

**PATENT COOPERATION TREATY**  
**PCT**  
**THIRD PARTY OBSERVATION**  
**(PCT Administrative Instructions Part 8)**

Applicant's or agent's file reference 0614-00149	
International application number PCT/US2022/033308	International filing date (day/month/year) 13 Jun 2022 (13/06/2022)
Applicant MIND MEDICINE, INC.	
Third party observation submitted by Sisi LI	Observation submitted on behalf of Porta Sophia
Date of submission(day/month/year) 26 Oct 2023 (26/10/2023)	Language of observation English

**Basis and contents of observation**

1. The observation is made on the basis of the claims in the international application as filed.
2. The observation comprises:  
References to documents: 5  
Uploaded copies of documents: 5
3. Further explanations:  
Uploaded copies of documents: 1

**Citation # 1 (Patent/utility model) (# uploaded documents: 1):**

Country code: US	Publication number: 20210183519	Document kind code: A1
Patent Applicant/Patent Owner: Eleusis Health Solutions US, Inc.	Title of invention: METHODS AND SYSTEMS FOR ENHANCING SAFETY OF PSYCHEDELIC DRUG THERAPIES	
Link to document:		
Publication Date: 17 Jun 2021 (17/06/2021)	Filing Date: 19 Oct 2018 (19/10/2018)	Priority Date:
Source of Abstract:	Accession number:	Publication Date of Abstract: Retrieval Date of Abstract:
Most relevant passages or drawings: [0011], [0012], [0013], [0029], [0041], [0044], [0052], [0053], [0071], [0084], [0085], [0094], [0096], [0101], [0102], [0103], [0104], [0107], [0108], [0130], [0134], [0135], [0137], [0138], [0143], [0149], [0164], [0165], [0166], [0184], [0185], [0186], [0187], [0190], [0197], claim 21, 25, 26, 96, 190, example 2		Relevant to Claims: 1-15, 17-19, 21-26

Brief explanation of relevance:

From <b>[0164]</b> "...<b>the invention involves monitoring patients undergoing treatment with psychedelic agents</b>..." relevant to WO2023278131 claims 1, 9, 21<br/><br/>From <b>[0165]</b> "...<b>Psychedelic agents useful as part of the invention include any compound capable of inducing an altered state of consciousness</b>... Psychedelic agents include 5-HT.sub.2A agonists (e.g., lysergic acid diethylamide (LSD), empathogenic agents (i.e., serotonin (5-HT) releasing agents; e.g., 3,4-methylenedioxymethamphetamine (MDMA)), and dissociative agents (i.e., N-Methyl-D-aspartate (NMDA) receptor agonists; e.g., ketamine)." relevant to WO2023278131 claims 1, 9, 12, 21<br/><br/>From <b>[0130]</b> "In some embodiments, <b>the system passively acquires data (e.g., language data) that indicates that a psychedelic dose is too high</b> ... <b>In any case, a third party may be notified to follow up with the patient, to temporarily suspend treatment, or both."</b> relevant to WO2023278131 claims 1<br/><br/>From <b>[0134]</b> "... <b>a network-connected computerized database </b>... <b>A system of the invention may include a software application (e.g., a patient-interface application, e.g., a mobile-device application) that accesses such a database conditionally</b> <b>or automatically to send one or more notifications, alerts, reports, or other information to a third party (e.g., to a computing platform (e.g., a remote database) or a clinical professional) for storage or analysis."</b> relevant to WO2023278131 claims 1, 4, 7, 9, 15<br/><br/>From <b>[0085]</b> "The methods and systems provided herein feature <b>automated language</b> <b>analysis to process and analyze one or more language samples obtained from a candidate or patient</b>... <b>(e.g., on a remote server in communication with the software application)</b>." relevant to WO2023278131 claims 1<br/><br/>Due to spatial constraints of the "Brief explanation of relevance" field, the content herein is abbreviated for pertinence.<br/><br/>From <b>[0103]</b> relevant to WO2023278131 claims 2, 4, 5, 8, 12, 18, 21<br/>From <b>[0104]</b> relevant to WO2023278131 claims 3, 4, 26<br/>From <b>[0138]</b> relevant to WO2023278131 claims 5<br/>From <b>claim 190</b> relevant to WO2023278131 claims 5<br/>From <b>[0137]</b> relevant to WO2023278131 claims 5, 8, 10, 25<br/>From <b>[0052]</b> relevant to WO2023278131 claims 6, 14<br/>From <b>[0053]</b> relevant to WO2023278131 claims 6, 14<br/>From <b>[0197]</b> relevant to WO2023278131 claims 7<br/>From <b>[0041]</b> relevant to WO2023278131 claims 8<br/>From <b>[0107]</b> relevant to WO2023278131 claims 8<br/>From <b>[0166]</b> relevant to WO2023278131 claims 9<br/>From <b>[0071]</b> relevant to WO2023278131 claims 10, 13<br/>From <b>[0011]</b> relevant to WO2023278131 claims 10, 21<br/>From <b>claim 25</b> relevant to WO2023278131 claims 10<br/>From <b>Example 2</b>. relevant to WO2023278131 claims 10<br/>From <b>[0184]</b> relevant to WO2023278131 claims 10<br/>From <b>[0185]</b> relevant to WO2023278131 claims 12, 25<br/>From <b>[0084]</b> relevant to WO2023278131 claims 11, 25<br/>From <b>[0108]</b> > relevant to WO2023278131 claims 11, 21, 25<br/>From <b>[0044]</b> relevant to WO2023278131 claims 12, 15, 18<br/>From <b>[0186]</b> </b>relevant to WO2023278131 claims 12<br/>From <b>[0094]</b> relevant to WO2023278131 claims 13, 21, 26<br/>From <b>claim 21</b> relevant to WO2023278131 claims 15<br/>From <b>[0143]</b> relevant to WO2023278131 claims 17<br/>From <b>[0101]</b> relevant to WO2023278131 claims 18<br/>From <b>[0102]</b> relevant to WO2023278131 claims 18<br/>From <b>[0135]</b> relevant to WO2023278131 claims 18<br/>From <b>[0012]</b> relevant to WO2023278131 claims 18<br/>From <b>claim 96 </b> relevant to WO2023278131 claims 19<br/>From <b>[0029]</b> relevant to WO2023278131 claims 19<br/>From <b>[0190]</b> relevant to WO2023278131 claims 19<br/>From <b>[0187]</b> </b> relevant to WO2023278131 claims 19<br/>From <b>[0096]</b> relevant to WO2023278131 claims 24<br/>From <b>[0149]</b> </b>relevant to WO2023278131 claims 25<br/>From <b>[0013]</b> </b> relevant to WO2023278131 claims 25

## Citation # 2 (Patent/utility model) (# uploaded documents: 1):

Country code: US	Publication number: 20170172522	Document kind code: A1	
Patent Applicant/Patent Owner: Joseph Insler		Title of invention: METHOD AND DEVICE FOR AUTOMATIC IDENTIFICATION OF AN OPIOID OVERDOSE AND INJECTION OF AN OPIOID RECEPTOR ANTAGONIST	
Link to document:			
Publication Date: 22 Jun 2017 (22/06/2017)	Filing Date: 22 Dec 2016 (22/12/2016)	Priority Date:	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: claim 1		Relevant to Claims: 11	
Brief explanation of relevance: From claim 1 "A method for detecting the need for providing assistance to an individual suspected of overdosing on an opiate, the method comprising, <b>(a) measuring continuously or intermittently one or more physiological parameters of the individual using a device</b>; (b) <b>triggering an alarm if the level of at least one of the one or more physiological parameters exceeds a threshold level specific to said parameter;</b> (c) continuing the measuring, and if the alarm was interrupted, suspending the alarm for a period of time and determining thereafter whether the level of the at least one of the one or more physiological parameters has returned to the threshold level; (d) triggering the alarm if, after said period of time, the level of the at least one of the one or more physiological parameters had not returned to the threshold level; (e) repeating steps (c) and (d) if in step (d) the alarm was interrupted, and if the alarm was not interrupted in either step (d) or (b) <b>within a fixed duration, transmitting a message to one or more contacts </b>(i) to convey that the individual had overdosed on an opiate and (ii) provide GPS coordinates of the individual" relevant to WO2023278131 claims 11 			

Pending processing

Citation # 3(Periodical article) (# uploaded documents:1):

Author: Reuben J. Strayer and Lewis S. Nelsen	Title of article: Adverse events associated with ketamine for procedural sedation in adults	Title of Periodical: American Journal of Emergency Medicine	Publication Date: Nov 2008 (11/2008)
Issue Number of Periodical: Volume 26 Issue 9	Publisher of Periodical:	Place of publication:	
Page range of article within periodical: Pages 985-1028	ISBN:	ISSN:	
DOI: 10.1016/j.ajem.2007.12.005.			
Most relevant passages or drawings: pages 991, 1009, 1014-1015		Relevant to Claims: 16, 20	
<p>Brief explanation of relevance:</p> <p>From page &lt;b&gt;991&lt;/b&gt; "...Hallucinations were noted in 6/32 cases and "nightmares and anxiety" occurred in 2/32 cases..." relevant to WO2023278131 claims 16, 20&lt;br/&gt;&lt;br/&gt;From page &lt;b&gt;1009&lt;/b&gt; "67 patients aged 6-43 y undergoing tonsillectomy at a Nigerian hospital received IV diazepam , 0.2 mg/kg (max 10 mg)&lt;br/&gt;5-10 min preinduction. The pharynx was then anesthetized with&lt;br/&gt;3-4 doses of 10% lidocaine spray (10 mg/dose). &lt;b&gt;Patients then received IM ketamine 5 mg/kg &lt;/b&gt;&lt;br/&gt;and were positioned in neck hyperextension with sandbags under the shoulders so that blood would flow anteriorly rather than posteriorly. &lt;b&gt;An additional dose of IV ketamine, 1 mg/kg, was given just before the commencement of the operation&lt;/b&gt;... &lt;b&gt; Cardiorespiratory status was continuously monitored by a nurse anesthetist. No psychiatric adverse event reporting methodology is presented&lt;/b&gt;...No cardiorespiratory adverse events occurred; specifically there were no cases of laryngospasm. No "emergency delirium" occurred, but &lt;b&gt;"patients were rather more restless than usual." The authors note a prolonged recovery time ranging from 40 min to 2 h. Postoperative vomiting occurred in 31% of patients.&lt;/b&gt;" relevant to WO2023278131 claims 16, 20&lt;br/&gt;&lt;br/&gt;From pages &lt;b&gt;1014-1015&lt;/b&gt; "&lt;b&gt;239 patients undergoing 247 assorted operations in a hospital in Guyana received IV ketamine,&lt;/b&gt;&lt;b&gt; 2&lt;/b&gt;&lt;b&gt;.2 mg/kg, or IM ketamine, 11 mg/kg,&lt;/b&gt;&lt;br/&gt;followed by supplemental smaller doses as needed with or without premedicant IM diazepam, 10-15 mg...Adverse event reporting methodology is not presented, however &lt;b&gt;cardiorespiratory status seemed to be continuously monitored in the anesthesiologist controlled operating room setting. The author reports that he saw all patients postoperatively and reviewed all nursing notes for complications.&lt;/b&gt;" relevant to WO2023278131 claims 16, 20</p>			

Pending

Citation # 4 (Patent/utility model) (# uploaded documents: 1):

Country code: US	Publication number: 20200337625	Document kind code: A1	
Patent Applicant/Patent Owner: INTERAXON INC.		Title of invention: SYSTEM AND METHOD FOR BRAIN MODELLING	
Link to document:			
Publication Date: 29 Oct 2020 (29/10/2020)	Filing Date: 24 Apr 2020 (24/04/2020)	Priority Date:	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: [0028], [0315]		Relevant to Claims: 17	
Brief explanation of relevance: From [0315] “<b>In the case of psychedelic therapy, </b>for example, the regulation of set, setting, and intensification of experience could be modulated and adjusted by a caregiver receiving outputs from the patient undergoing therapy in real time through which<b> the patient’s experience is modeled predictively in order to understand how their experience and temporal state could be anticipated to alter or vary throughout the course of treatment,</b> in relation to their particular interaction and integration with the therapy. In order to optimize the efficacy of a psychedelic treatment, it is especially important to identify and determine the way in which a patient will experience its corresponding effects, such that success of treatment will vary depending on the specific and particular level of receptivity and comfortability with the therapeutic experience.” relevant to WO2023278131 claims 17  From [0028] “According to a further aspect, there is provided <b>a non-transitory computer readable medium comprising a computer readable memory storing computer executable instructions thereon that when executed by a computer cause the computer to perform a method as described herein.</b>” relevant to WO2023278131 claims 17			

Citation # 5(Web page) (# uploaded documents:1):

Author:	Title of Page Or Article: Providence Care Ketamine Clinic; a new hope for treatment resistant depression		
URL: <a href="https://providencecare.ca/providence-care-ketamine-clinic-a-new-hope-for-treatment-resistant-depression/">https://providencecare.ca/providence-care-ketamine-clinic-a-new-hope-for-treatment-resistant-depression/</a>			
DOI:			
Name of Website: Providence Care	Publication Date: 29 Jan 2020 (29/01/2020)	Retrieval Date: 26 Oct 2023 (26/10/2023)	
Most relevant passages or drawings: Quote from webpage		Relevant to Claims: 20	
Brief explanation of relevance: From webpage, picture showing Gary Crawford at Providence Care’s Ketamine Clinic with a wearable device connected to a heart rate and blood pressure monitor “Gary and Jan Crawford at <b>Providence Care’s Ketamine Clinic</b>. Gary started coming to the clinic in June 2019... <b>The ketamine is given by an intravenous (IV) infusion and lasts about 40 minutes, during which their heart rate and blood pressure are monitored.</b><b>” </b>relevant to WO2023278131 claims 20			